Sign In
Buy MBX
$48.40
+2.01 (+4.33%)
At Close: Jun 24, 2026
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
08:00am, Thursday, 23'rd Apr 2026
CARMEL, Ind. and BURLINGTON, Mass.
Microbix Engages with Diagnostics Industry Experts
07:00am, Monday, 20'th Apr 2026
Releasing Episodes of Season Two of "Diagnostics: Beyond the Lab" Podcast MISSISSAUGA, ON / ACCESS Newswire / April 20, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life scie
Microbix Presenting at the 2026 Bloom Burton Conference
07:00am, Thursday, 16'th Apr 2026
MISSISSAUGA, ON / ACCESS Newswire / April 16, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces it will be attending
Critical Analysis: Immune Therapeutics (OTCMKTS:IMUN) & MBX Biosciences (NASDAQ:MBX)
04:09am, Saturday, 04'th Apr 2026
Immune Therapeutics (OTCMKTS:IMUN - Get Free Report) and MBX Biosciences (NASDAQ: MBX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the t
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 03'rd Apr 2026
CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pr
MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know
11:44am, Thursday, 26'th Mar 2026
The president & CEO of MBX Biosciences reported the acquisition of 18,500 indirectly held shares for about $526,000 on March 13, 2026. The indirect holdings (486,777 shares) are maintained via the P.
MBX Biosciences, Inc. (NASDAQ:MBX) Given Average Recommendation of “Moderate Buy” by Brokerages
02:50am, Thursday, 26'th Mar 2026
Shares of MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve research firms that are presently covering the company, MarketBea
Microbix Biosystems Inc. (MBX:CA) Shareholder/Analyst Call Transcript
03:25pm, Wednesday, 25'th Mar 2026
Microbix Biosystems Inc. (MBX:CA) Shareholder/Analyst Call Transcript
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
08:00am, Thursday, 12'th Mar 2026
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for o
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
08:00am, Tuesday, 10'th Mar 2026
CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pr
Microbix's Clot-Buster Drug Project Advances
07:00am, Tuesday, 10'th Mar 2026
Drug Substance Manufacturing Methods Modernized MISSISSAUGA, ON / ACCESS Newswire / March 10, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufactur
In the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows.
CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pr
MBX Biosciences to Participate in Upcoming March Investor Conferences
08:00am, Monday, 23'rd Feb 2026
CARMEL, Ind., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel pr
Microbix Biosystems Q1 Earnings Call Highlights
04:46am, Sunday, 15'th Feb 2026
Microbix Biosystems (TSE: MBX) management said fiscal first-quarter results showed sequential improvement and early signs of a rebound following what CEO Cameron Groome described as a "down year" in 2
